secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2022-05-11T23:59:59+00:00
Accession:  0001867096-22-000056
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xeris Q1 net product revenue $21.9M (+33% pro forma); net loss $33.7M; reaffirms FY22 guidance
--------------------------------------------------------------------------------

- Q1 net product revenue $21.9M, up 33% pro forma vs prior year; net loss $33.7M ($0.25/share).
- Cash and investments $132.1M at quarter end; completed $100M draw on new $150M Hayfin term loan.
- Affirms 2022 guidance: revenue $105M-$120M, year-end cash $90M-$110M, cash flow breakeven by end-2023.
- Gvoke prescriptions topped 30,000 in Q1, retail TRx market share ~22%; launched Recorlev and Gvoke Kit.
- Entered $30M securities purchase agreement with Armistice Capital; issued ~10.2M shares and warrants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709622000056/0001867096-22-000056-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709622000056/xers-20220511.htm
  HTML page:      https://secwatch.observer/filing/0001867096-22-000056

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer